1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. 2018; Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. DOI:
10.3322/caac.21492. PMID:
30207593.
2. IARC working group on the evaluation of carcinogenic risks to humans: some industrial chemicals. 1994; Lyon, 15-22 February 1994. IARC Monogr Eval Carcinog Risks Hum. 60:1–560. PMID:
7869568. PMCID:
PMC7681540.
3. Konturek PC, Konturek SJ, Brzozowski T. 2009; Helicobacter pylori infection in gastric cancerogenesis. J Physiol Pharmacol. 60:3–21. PMID:
19826177.
4. Kwak HW, Choi IJ, Cho SJ, et al. 2014; Characteristics of gastric cancer according to Helicobacter pylori infection status. J Gastroenterol Hepatol. 29:1671–1677. DOI:
10.1111/jgh.12605. PMID:
24730518.
5. Helicobacter and Cancer Collaborative Group. 2001; Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut. 49:347–353. DOI:
10.1136/gut.49.3.347. PMID:
11511555. PMCID:
PMC1728434.
6. Ford AC, Yuan Y, Moayyedi P. 2020; Helicobacter pylori eradication therapy to prevent gastric cancer: systematic review and meta-analysis. Gut. 69:2113–2121. DOI:
10.1136/gutjnl-2020-320839. PMID:
32205420.
7. Ma JL, Zhang L, Brown LM, et al. 2012; Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J Natl Cancer Inst. 104:488–492. DOI:
10.1093/jnci/djs003. PMID:
22271764. PMCID:
PMC3309129.
8. Rugge M, Meggio A, Pravadelli C, et al. 2019; Gastritis staging in the endoscopic follow-up for the secondary prevention of gastric cancer: a 5-year prospective study of 1755 patients. Gut. 68:11–17. DOI:
10.1136/gutjnl-2017-314600. PMID:
29306868.